Covered recipient · General Payments record
BERTRAND P COLE
Allopathic & Osteopathic Physicians Preventive Medicine Addiction Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$2,439.70
62 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,356.73 | 58 |
| Travel and Lodging | $1,082.97 | 4 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $1,589.68 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $174.27 | 6 |
| Merck Sharp & Dohme Corporation | $88.24 | 6 |
| Indivior Inc. | $84.22 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $79.73 | 5 |
| Janssen Pharmaceuticals, Inc | $62.23 | 4 |
| Collegium Pharmaceutical, Inc. | $57.65 | 3 |
| Lilly USA, LLC | $52.19 | 4 |
| GlaxoSmithKline, LLC. | $42.92 | 3 |
| SANOFI-AVENTIS U.S. LLC | $28.40 | 2 |
| Shionogi Inc | $27.11 | 2 |
| Amgen Inc. | $26.04 | 1 |
| Astellas Pharma US Inc | $22.98 | 1 |
| BioDelivery Sciences International, Inc. | $20.92 | 1 |
| Teva Pharmaceuticals USA, Inc. | $19.87 | 1 |
| AstraZeneca Pharmaceuticals LP | $18.06 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.33 | 1 |
| Pernix Therapeutics Holdings, Inc. | $13.97 | 1 |
| Kaleo, Inc. | $13.89 | 1 |
Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BERTRAND P COLE
NPI 1184618852 · CMS profile ID 53045
Allopathic & Osteopathic Physicians / Preventive Medicine / Addiction Medicine
SOMERSWORTH, NH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BERTRAND P COLE, NPI 1184618852, CMS profile ID 53045. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). BERTRAND P COLE, NPI 1184618852, CMS profile ID 53045. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- BERTRAND P COLE, NPI 1184618852, CMS profile ID 53045, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
62 matching records · $2,439.70 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–62 of 62.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $19.87 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697835683 | CMS |
| PFIZER INC. | $101.27 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671926133 | CMS |
| PFIZER INC. | $540.14 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671926135 | CMS |
| PFIZER INC. | $293.28 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671926137 | CMS |
| PFIZER INC. | $427.93 | 01/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671926139 | CMS |
| PFIZER INC. | $7.77 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671866059 | CMS |
| PFIZER INC. | $2.83 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671866293 | CMS |
| Pernix Therapeutics Holdings, Inc. | $13.97 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703311481 | CMS |
| Lilly USA, LLC | $14.64 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657718803 | CMS |
| Shionogi Inc | $12.92 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688777773 | CMS |
| PFIZER INC. | $3.07 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671866017 | CMS |
| PFIZER INC. | $13.24 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671891805 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2023
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $870,228.90 | 54 |
| PY2024 | Principal investigator | $1,905,180.28 | 179 |
| PY2023 | Principal investigator | $1,443,179.04 | 289 |
| PY2022 | Principal investigator | $251,564.05 | 26 |
| PY2021 | Principal investigator | $127,528.47 | 7 |
| PY2020 | Principal investigator | $6,130.68 | 3 |
| PY2019 | Principal investigator | $167,873.49 | 23 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
54 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $1,187.90 | 12/16/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738060 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,800.00 | 11/26/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185546003 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $398.00 | 11/25/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192157624 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,800.00 | 11/14/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185546001 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,310.00 | 11/12/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185546009 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 11/10/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956553 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 10/23/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956559 |
| Principal investigator 1 | ModernaTX, Inc. | $1,950.00 | 10/23/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956561 |
| Principal investigator 1 | ModernaTX, Inc. | $2,100.00 | 10/23/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956563 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 10/23/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956565 |
| Principal investigator 1 | ModernaTX, Inc. | $2,142.00 | 10/17/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956557 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,883.86 | 10/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192157628 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $849.66 | 09/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192157634 |
| Principal investigator 1 | PFIZER INC. | $4,700.00 | 08/22/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228787909 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,212.04 | 08/13/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192155197 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $686.00 | 08/06/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192155193 |
| Principal investigator 1 | PFIZER INC. | $450.00 | 08/06/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228767530 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $49.00 | 07/23/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192157631 |
| Principal investigator 1 | PFIZER INC. | $596.95 | 07/11/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228789609 |
| Principal investigator 1 | PFIZER INC. | $46,281.55 | 06/27/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228777775 |
| Principal investigator 1 | PFIZER INC. | $2,927.40 | 06/26/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228775811 |
| Principal investigator 1 | PFIZER INC. | $43,277.85 | 06/21/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228777200 |
| Principal investigator 1 | PFIZER INC. | $54,265.63 | 06/21/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228790466 |
| Principal investigator 1 | PFIZER INC. | $65,833.25 | 06/14/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228723466 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,117.96 | 06/06/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185546013 |
| Principal investigator 1 | PFIZER INC. | $36,402.38 | 06/06/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228775800 |
| Principal investigator 1 | ModernaTX, Inc. | $1,690.00 | 06/04/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956567 |
| Principal investigator 1 | PFIZER INC. | $7,740.00 | 06/04/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228793252 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $554.18 | 05/28/2025 | Non-covered Recipient Entity Activmed Practices And Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715350 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $610.54 | 05/21/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192157616 |
| Principal investigator 1 | PFIZER INC. | $123,904.62 | 04/29/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228798161 |
| Principal investigator 1 | PFIZER INC. | $13,902.10 | 04/25/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228781059 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $452.93 | 04/24/2025 | Non-covered Recipient Entity Activmed Practices And Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715348 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,763.02 | 04/23/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192157620 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,952.46 | 04/17/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER, PA | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity | No dispute reported | 06/30/2026 | 1185546007 |
| Principal investigator 1 | PFIZER INC. | $60,241.16 | 04/10/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723186 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,047.40 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192157611 |
| Principal investigator 1 | PFIZER INC. | $264.20 | 04/01/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228719541 |
| Principal investigator 1 | PFIZER INC. | $2,103.64 | 04/01/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228796018 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $190,369.79 | 03/28/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity | No dispute reported | 06/30/2026 | 1185546015 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,088.11 | 03/27/2025 | Non-covered Recipient Entity Activmed Practices And Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715340 |
| Principal investigator 1 | PFIZER INC. | $10,300.00 | 03/12/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228779876 |
| Principal investigator 1 | ModernaTX, Inc. | $1,803.39 | 02/27/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252956555 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,140.50 | 02/25/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192155201 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $5,163.68 | 02/20/2025 | Non-covered Recipient Entity Activmed Practices And Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715336 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,589.26 | 02/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192155206 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,216.72 | 01/30/2025 | Non-covered Recipient Entity Activmed Practices And Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715334 |
| Principal investigator 1 | PFIZER INC. | $3,186.56 | 01/29/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228799808 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $24,800.00 | 01/28/2025 | Non-covered Recipient Entity Activmed Practices And Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226089042 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,084.00 | 01/15/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185546005 |
| Principal investigator 1 | PFIZER INC. | $6,456.45 | 01/09/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228801233 |
| Principal investigator 1 | PFIZER INC. | $812.28 | 01/08/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228800202 |
| Principal investigator 1 | AstraZeneca UK Limited | $27,159.96 | 01/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185546011 |
| Principal investigator 1 | PFIZER INC. | $7,310.52 | 01/01/2025 | Non-covered Recipient Entity ActivMed Practices Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228802030 |